Abstract
Hipersensitivite reaksiyonları, antineoplastik ilaç
uygulamalarında ortaya çıkan acil müdahale gerektiren durumlardır. Akciğer,
meme ve over kanseri gibi malign hastalıklarda kür, kontrol ve palyasyon
amacıyla uygulanan paklitaksel, hastalarda %8-45 oranında hiperpensitivite
reaksiyonuna neden olmaktadır. Dispne, ürtiker, hipotansiyon, eritem, göğüs ve
sırt ağrısı bu hastaların hipersensitivite ile ilişkili başlıca yakınmalarıdır.
Onkoloji hemşirelerinin, kemoterapi ile ilişkili hipersensitivite
reaksiyonlarının önlenmesi, kontrolü ve yönetiminde önemli sorumlulukları
vardır. Olgu sunumlarımız, paklitaksel uygulanan hastalarda gelişen
hipersensitivite reaksiyonları ve hemşirelik girişimleri ele alınarak
tartışılmıştır.
References
- 1. Gerper RV. Chemotherapy and Biotherapy- Induced Hypersensitivity Reactions. J Infus Nurs 2009; 32(3):157-165
- 2. Ruggiero A et al. Incidence, Clinical Features and Management of Hypersensitivity Reactions to Chemotheropeutic Drugs in children with Cancer. Eur J Clin Pharmacol 2013; 69: 1739-1746.
- 3. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4. 03. Published date June 14, 2010. http://evs. nci. nih. gov/ft p1/CTCAE/CTCAE_4. 03_2010-06-14_QuickReference_5x7.pdf (Erişim tarihi: 05.02.2016)
- 4. Özcan K, Tuna İ, Yılmaz K, Zorlu R, Mollaoğlu M, Şen F. Hipersensitivite reaksiyonları. Can G (editör). Onkoloji hemşireliğinde kanıttan Uygulamaya-Konsensus2014.2015; 53-61
- 5. Guidelines for Management of Intravenous Systemic Anti- Cancer Therapy Related Hypersensitivity Reactions including Anaphylaxis http://www.londoncancer.org/media/79795/London-Cancer-Chemo-Hypersensitivity-Guideline-v1-FINAL-VERSION.pdf (2015) Erişim tarihi: 02.25.2016
- 6. Makrilia N, Syrigou E, Kaklamonos I, et al. Hipersensitiviy Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review. Met Based Drugs 2010;1-11.
- 7. Joerger M. Prevention and handling of acute allergic and infusion reactions in oncology.Ann Oncol 2012; 23(10): 313-9.
- 8. Vogel WH. Infusion Reactions: Diagnosis, Assessment and Management. Clin J Oncol Nurs. 2010;14(2):E10-12
- 9. Muallaoğlu S, Disel U, Mertsoylu H, Besen A, Karadeniz C, Sumbul TA, Abali HA, Ozyilkan O. Acute infusion reactions to chemotherapeutic drugs: a single institute experience. J BUON 2013; 18(1): 261-267
- 10. Banerji A, Lax T, Guyer A, Hurwitz S, Camargo CA Jr, Long AA. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract 2014;2(4):428-33.
- 11. Henry A, Charpiat B, Perol M, Vial T, de Saint Hilaire PJ, Descotes J. Paclitaxel Hypersensitivity Reactions: Assessment of the Utility of a Test-Dose Program. Cancer J 2006; 12 (3):237-245
- 12. Lal SL, Gerber LD, Lau J, Dana W. Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center. Support Care Cancer 2009 ;17(10):1311–1315
- 13. Yahata H, Saito M, Sendo T, Itoh Y, Uchida M, Hirakawa T, Nakano H, Oishi R. Prophylactic effect of pemurolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer. Int.J.Cancer 2006;118(10): 2636-2638
- 14. Tham EH, Cheng YK, Tay MH, Alcasabas AP, Shek LP. Evaluation and management of hypersensitivity reactions to chemotherapy agents. 2015; 91(1073): 145-50.
- 15. Breslin, S. Cytokine-release syndrome: Overview and nursing implications. Clin J Oncol Nurs 2007; 11(1, Suppl.): 37–42.
- 16. Gobel, B.H. Chemotherapy-induced hypersensitivity reactions. Oncology Nursing Forum 2005; 32(5): 1027–1035
- 17. Kang, S.P., Saif, M.W. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer—Identification, prevention, and management. Journal of Supportive Oncology, 2007;5(9):451–457.
Abstract
References
- 1. Gerper RV. Chemotherapy and Biotherapy- Induced Hypersensitivity Reactions. J Infus Nurs 2009; 32(3):157-165
- 2. Ruggiero A et al. Incidence, Clinical Features and Management of Hypersensitivity Reactions to Chemotheropeutic Drugs in children with Cancer. Eur J Clin Pharmacol 2013; 69: 1739-1746.
- 3. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4. 03. Published date June 14, 2010. http://evs. nci. nih. gov/ft p1/CTCAE/CTCAE_4. 03_2010-06-14_QuickReference_5x7.pdf (Erişim tarihi: 05.02.2016)
- 4. Özcan K, Tuna İ, Yılmaz K, Zorlu R, Mollaoğlu M, Şen F. Hipersensitivite reaksiyonları. Can G (editör). Onkoloji hemşireliğinde kanıttan Uygulamaya-Konsensus2014.2015; 53-61
- 5. Guidelines for Management of Intravenous Systemic Anti- Cancer Therapy Related Hypersensitivity Reactions including Anaphylaxis http://www.londoncancer.org/media/79795/London-Cancer-Chemo-Hypersensitivity-Guideline-v1-FINAL-VERSION.pdf (2015) Erişim tarihi: 02.25.2016
- 6. Makrilia N, Syrigou E, Kaklamonos I, et al. Hipersensitiviy Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review. Met Based Drugs 2010;1-11.
- 7. Joerger M. Prevention and handling of acute allergic and infusion reactions in oncology.Ann Oncol 2012; 23(10): 313-9.
- 8. Vogel WH. Infusion Reactions: Diagnosis, Assessment and Management. Clin J Oncol Nurs. 2010;14(2):E10-12
- 9. Muallaoğlu S, Disel U, Mertsoylu H, Besen A, Karadeniz C, Sumbul TA, Abali HA, Ozyilkan O. Acute infusion reactions to chemotherapeutic drugs: a single institute experience. J BUON 2013; 18(1): 261-267
- 10. Banerji A, Lax T, Guyer A, Hurwitz S, Camargo CA Jr, Long AA. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract 2014;2(4):428-33.
- 11. Henry A, Charpiat B, Perol M, Vial T, de Saint Hilaire PJ, Descotes J. Paclitaxel Hypersensitivity Reactions: Assessment of the Utility of a Test-Dose Program. Cancer J 2006; 12 (3):237-245
- 12. Lal SL, Gerber LD, Lau J, Dana W. Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center. Support Care Cancer 2009 ;17(10):1311–1315
- 13. Yahata H, Saito M, Sendo T, Itoh Y, Uchida M, Hirakawa T, Nakano H, Oishi R. Prophylactic effect of pemurolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer. Int.J.Cancer 2006;118(10): 2636-2638
- 14. Tham EH, Cheng YK, Tay MH, Alcasabas AP, Shek LP. Evaluation and management of hypersensitivity reactions to chemotherapy agents. 2015; 91(1073): 145-50.
- 15. Breslin, S. Cytokine-release syndrome: Overview and nursing implications. Clin J Oncol Nurs 2007; 11(1, Suppl.): 37–42.
- 16. Gobel, B.H. Chemotherapy-induced hypersensitivity reactions. Oncology Nursing Forum 2005; 32(5): 1027–1035
- 17. Kang, S.P., Saif, M.W. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer—Identification, prevention, and management. Journal of Supportive Oncology, 2007;5(9):451–457.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Articles |
| Authors | |
| Publication Date | April 15, 2018 |
| Submission Date | June 14, 2017 |
| Acceptance Date | January 10, 2018 |
| Published in Issue | Year 2018 Volume: 11 Issue: 1 |
Cite
MEU Journal of Health Sciences Assoc was began to the publishing process in 2008 under the supervision of Assoc. Prof. Gönül Aslan, Editor-in-Chief, and affiliated to Mersin University Institute of Health Sciences. In March 2015, Prof. Dr. Caferi Tayyar Şaşmaz undertook the Editor-in Chief position and since then he has been in charge.
Publishing in three issues per year (April - August - December), it is a multisectoral refereed scientific journal. In addition to research articles, scientific articles such as reviews, case reports and letters to the editor are published in the journal. Our journal, which has been published via e-mail since its inception, has been published both online and in print. Following the Participation Agreement signed with TÜBİTAK-ULAKBİM Dergi Park in April 2015, it has started to accept and evaluate online publications.
Mersin University Journal of Health Sciences have been indexed by Turkey Citation Index since November 16, 2011.
Mersin University Journal of Health Sciences have been indexed by ULAKBIM Medical Database from the first issue of 2016.
Mersin University Journal of Health Sciences have been indexed by DOAJ since October 02, 2019.
Article Publishing Charge Policy: Our journal has adopted an open access policy and there is no fee for article application, evaluation, and publication in our journal. All the articles published in our journal can be accessed from the Archive free of charge.
This work is licensed with Attribution-NonCommercial 4.0 International.